医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Clinical Innovations hires Rebecca Liu as VP, general manager for CI Medical Instruments in China

2019年11月19日 PM08:00
このエントリーをはてなブックマークに追加


 

SALT LAKE CITY

Clinical Innovations, one of the world’s largest medical device companies focused on labor and delivery and neonatal intensive care, announced today that it has hired Rebecca Liu as vice president and general manager of Greater China for CI Medical Instruments.

The hiring of Liu, a deeply experienced executive who’s driven double-digit growth for numerous U.S. healthcare companies in China, marks an acceleration of Clinical Innovations’ Chinese market strategy. Clinical Innovations established CI Medical Instruments, a Shanghai-based wholly owned subsidiary, in 2018 amid a streak of international expansion that deepened the company’s presence in Western Europe, Australia and Asia.

“Building on our success in China, Rebecca will support our international growth strategy and allow us to better serve the fast-developing Asian market,” said Steve Cash, Clinical Innovations’ chief sales officer. “Rebecca’s experience leading across organizations and achieving outstanding results makes her perfectly suited for this task.”

Clinical Innovations products, including the Kiwi® Vacuum-Assisted Delivery System, babyLance™ Safety heel stick, Koala® Intrauterine Pressure Catheter, and ebb® Complete Tamponade System are used to help millions of mothers and babies in more than 90 countries each year. The Salt Lake City-based company is owned by leading investment firm EQT.

Liu was most recently vice president and general manager of Greater China for life science products and clinical diagnosis manufacturer Bio-Rad Laboratories, overseeing all operations in mainland China and Taiwan. Before that, she was the general manager for China, Hong Kong and Taiwan for Cook Medical and country manager for VWR China.

Responsibilities included overseeing sales, supply chain and regulatory affairs while building business and teams from the ground up. Earlier in her career, Liu worked at the American headquarters of Greenheck Fan Corp., leading the establishment of its first manufacturing plant outside the U.S.

“I am honored to join Clinical Innovations and contribute to its mission of improving healthcare around the world,” Liu said. “With the company’s innovative products and focus on training and education, I know we can make a significant, positive impact throughout China and the region. I am thrilled that more Chinese mothers, babies and families will benefit from our right strategy in the region.”

Liu is active with the American Chamber of Commerce and Advanced Medical Technology Association (AdvaMed). She holds an MBA from the University of Illinois at Chicago and a bachelor’s degree in law from Shanghai University Law School.

About Clinical Innovations

Clinical Innovations is one of the largest medical device companies exclusively focused on labor and delivery and neonatal intensive care. The company is a market-leader in several categories with products such as the Koala® Intrauterine Pressure Catheter, Kiwi® Vacuum-Assisted Delivery System, ROM Plus® Rupture of Membranes Test, traxi® Panniculus Retractor, ClearView® Uterine Manipulator and the babyLance™ Safety heel stick. Clinical Innovations is expanding its global presence while directly researching and developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world. Clinical Innovations is an EQT portfolio company. For more information, visit clinicalinnovations.com.

About EQT

EQT is a leading investment firm with approximately EUR 62 billion in raised capital since inception. EQT funds have portfolio companies in Europe, Asia and the U.S. with total sales of more than EUR 21 billion and approximately 127,000 employees. EQT is an active investor and owner in the health care sector, including investments in LaoBaiXing Pharmacy, Aldevron, Certara, WS Audiology, and Galderma. EQT invests in good companies across the world with a mission to help them develop into great and sustainable companies. For more information, visit EQTpartners.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005305/en/

CONTACT

Martha Arendt, Aileron Communications

312.629.9400, marendt@aileroninc.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Konkuk University Research Team Identifies Drought-tolerant Process of Plants at the Molecular Level
  • Dabur Research Foundation™ and Flowerkist Incorporated™ to Co-Develop and Launch a Wide Range of CBD Infused Topical Therapeutic and Age Management Products
  • Osaka University and Fuzionaire Radioisotope Technologies K.K. to Jointly Develop Astatine-211 Radiopharmaceuticals and Fluorine-18 Radiotracers for Oncology
  • Effepharm Announced Acquisitions and New R&D Center Establishment
  • Indee Labs Issued United States and International Patents for Intracellular Delivery System